|By PR Newswire||
|January 13, 2014 03:10 AM EST||
BREDA, The Netherlands and GHENT, Belgium, January 13, 2014 /PRNewswire/ --
Enters into pilot research agreement with Boehringer Ingelheim
arGEN-X, a clinical stage human therapeutic antibody company, announces the attainment of two important success milestones in its SIMPLE Antibody™ research and product development collaboration with Shire. The milestones, which trigger undisclosed payments from Shire, relate to demonstration of in vivo proof of concept for one of the ongoing antibody discovery programs.
Initiated in February 2012, the collaboration is focused on creating human therapeutic antibodies against complex targets implicated in severe, rare genetic diseases. Shire has an option to license the most promising antibody leads for further development and commercialization worldwide, in return for fee, milestone and royalty payments.
"Yet again the functional diversity of SIMPLE Antibodies™ has enabled our scientists to set a precedent in validating highly complex targets both in vitro and in vivo and identifying antibody leads with exciting therapeutic potential," said Hans de Haard, PhD, Chief Scientific Officer of arGEN-X. "We value our collaboration with Shire very highly and continue to make excellent progress through the outstanding joint efforts of our teams."
"We are very impressed by the productivity and consistent success of our therapeutic antibody collaboration with arGEN-X," said Albert Seymour, Head of Discovery Biology and Translational Research at Shire.
arGEN-X today also announced the initiation of a new pilot research agreement with Boehringer Ingelheim. No further details are being disclosed at this stage.
arGEN-X is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody technologies. arGEN-X is creating first and best in class antibody therapeutics with highly differentiated target product profiles. Its therapeutic antibody programs, focused on cancer and autoimmune indications, are designed to deliver tangible benefits to patients with these diseases.
Jan. 20, 2017 06:30 PM EST Reads: 5,444
Jan. 20, 2017 05:45 PM EST Reads: 2,085
Jan. 20, 2017 05:30 PM EST Reads: 1,463
Jan. 20, 2017 05:15 PM EST Reads: 4,943
Jan. 20, 2017 05:15 PM EST Reads: 3,801
Jan. 20, 2017 05:15 PM EST Reads: 3,531
Jan. 20, 2017 04:45 PM EST Reads: 1,071
Jan. 20, 2017 03:00 PM EST Reads: 1,641
Jan. 20, 2017 02:30 PM EST Reads: 1,121
Jan. 20, 2017 02:15 PM EST Reads: 608
Jan. 20, 2017 01:30 PM EST Reads: 5,729
Jan. 20, 2017 01:30 PM EST Reads: 5,233
Jan. 20, 2017 01:30 PM EST Reads: 3,591
Jan. 20, 2017 01:00 PM EST Reads: 2,575
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Jan. 20, 2017 12:30 PM EST Reads: 4,345